Abstract
The prevention and management of QT interval prolongation and torsades de pointes often depends on the underlying etiology. Drugs and electrolyte imbalances are the major causes of acquired long QT syndrome, and prevention strategies include identifying and discontinuing or substituting the offending drug and correcting electrolyte abnormalities. Lifestyle modification, genetic testing, and β-adrenergic receptor blockade are risk mitigation strategies for patients with the congenital long QT syndrome. Left cardiac sympathetic denervation, implantable cardioverter-defibrillator, magnesium sulfate and overdrive cardiac pacing are currently used in the management of TdP, although a significant number of cases are not adequately managed. This chapter discusses the approaches and current therapies for the prevention and management of long QT syndrome. The chapter also explores novel approaches such genome editing, RNA interference, and hormone therapy in the management of QT interval prolongation and torsades de pointes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
